Trial intelligence / Profile preview

AG-014699 in Diabetic Macular Edema

NCT00457470Phase 2

Key facts

Status: Withdrawn
Start: Jun 2007
Sponsor: Pfizer
Modality: Small Molecules

Drugs: rucaparib
Conditions: diabetic macular edema (DME)

Overview

Phase 2 trial of rucaparib in diabetic macular edema (DME), sponsored by Pfizer. Primary endpoint: Change of retinal thickness at Day 25. Planned start Jun 2007; status: withdrawn.

Design

1 arm

AG-014699
Subjects receiving AG-014699

Endpoints

Primary

Change of retinal thicknessDay 25

Secondary

Proportion of subjects with reduction in retinal thickness2 months
Change in retinal thickness2 months
Change in visual acuity2 months
Proportion of eyes experiencing an improvement in the degree of retinopathyDay 28

Beyond the preview

Go deeper on NCT00457470.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00457470.